Rowlandmiller & PARTNERS.ADV Acquires 40 Shares of Amgen Inc. (NASDAQ:AMGN)

Rowlandmiller & PARTNERS.ADV raised its stake in Amgen Inc. (NASDAQ:AMGN) by 0.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 17,588 shares of the medical research company’s stock after buying an additional 40 shares during the period. Amgen comprises about 1.2% of Rowlandmiller & PARTNERS.ADV’s portfolio, making the stock its 24th biggest position. Rowlandmiller & PARTNERS.ADV’s holdings in Amgen were worth $5,480,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in the stock. Tallon Kerry Patrick bought a new stake in shares of Amgen in the 4th quarter valued at $270,000. Brighton Jones LLC boosted its position in Amgen by 23.5% during the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after acquiring an additional 5,226 shares during the last quarter. Newbridge Financial Services Group Inc. bought a new stake in Amgen during the fourth quarter valued at $102,000. Wingate Wealth Advisors Inc. bought a new stake in Amgen during the fourth quarter valued at $52,000. Finally, International Private Wealth Advisors LLC boosted its position in Amgen by 7.5% during the fourth quarter. International Private Wealth Advisors LLC now owns 903 shares of the medical research company’s stock valued at $235,000 after acquiring an additional 63 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on AMGN. Erste Group Bank lowered Amgen from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 8th. Johnson Rice set a $294.00 price target on Amgen in a report on Wednesday, March 5th. Royal Bank of Canada cut their price target on Amgen from $324.00 to $320.00 and set an “outperform” rating on the stock in a report on Friday, May 2nd. UBS Group restated a “neutral” rating and set a $315.00 price target (down from $319.00) on shares of Amgen in a report on Friday, May 2nd. Finally, Wall Street Zen upgraded shares of Amgen from a “buy” rating to a “strong-buy” rating in a report on Sunday, May 18th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, nine have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Amgen has an average rating of “Hold” and an average target price of $309.22.

Amgen Trading Up 1.2%

Shares of Amgen stock opened at $293.43 on Wednesday. The firm has a market cap of $157.78 billion, a PE ratio of 38.86, a P/E/G ratio of 2.63 and a beta of 0.51. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. The stock has a fifty day moving average price of $280.93 and a 200-day moving average price of $285.41.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.18 by $0.72. The business had revenue of $8.15 billion during the quarter, compared to the consensus estimate of $8.05 billion. Amgen had a net margin of 12.24% and a return on equity of 176.32%. The firm’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter last year, the company posted $3.96 earnings per share. Equities research analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Insiders Place Their Bets

In other Amgen news, SVP Rachna Khosla sold 1,500 shares of the firm’s stock in a transaction on Thursday, June 5th. The stock was sold at an average price of $289.68, for a total value of $434,520.00. Following the completion of the sale, the senior vice president now directly owns 8,162 shares of the company’s stock, valued at $2,364,368.16. This trade represents a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Company insiders own 0.76% of the company’s stock.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.